|
Regimen used by combination
|
|
| Cisplatin-based doublet |
31 (50%) |
| Carboplatin-based doublet |
30 (48%) |
| Vinorelbine in combination with a platinum agent |
26 (42%) |
| Cisplatin plus vinorelbine |
16 (23%) |
| Carboplatin plus vinorelbine |
10 (16%) |
| Carboplatin plus paclitaxel |
8 (13%) |
| Cisplatin plus pemetrexed |
8 (13%) |
| Carboplatin plus pemetrexed |
7 (11%) |
| Cisplatin plus gemcitabine |
7 (11%) |
| Carboplatin plus gemcitabine |
5 (8%) |
| Pemetrexed |
1 (2%) |
|
Treatment modifications
|
|
| Completed treatment without dose reduction |
37 (60%) |
| Dose reduction required |
17 (27%) |
| Early treatment discontinuation |
11 (18%) |
|
Toxicity
|
|
| Grade 3–4 haematological toxicity |
24 (39%) |
| Grade 3–4 neutropenia |
22 (35%) |
| Grade 3–4 anaemia |
4 (6%) |
| Grade 3–4 thrombocytopenia |
1 (2%) |
| Hospital admission |
18 (29%) |
